The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy
Share this
Author
Date
2018Published in
Journal of Thoracic Disease, 2077-6624, Vol 10, Supp 33, 2018, pag S4096–S4100
Source's URL
http://jtd.amegroups.com/article/view/24593/htmlMetadata
Show full item recordThe following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International